MX2017012708A - Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo. - Google Patents
Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo.Info
- Publication number
- MX2017012708A MX2017012708A MX2017012708A MX2017012708A MX2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A MX 2017012708 A MX2017012708 A MX 2017012708A
- Authority
- MX
- Mexico
- Prior art keywords
- ester
- dry eye
- therapeutic agent
- methenolone
- nandrolone
- Prior art date
Links
- 208000003556 Dry Eye Syndromes Diseases 0.000 title abstract 6
- 206010013774 Dry eye Diseases 0.000 title abstract 6
- 150000002148 esters Chemical class 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 5
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 229960003578 metenolone Drugs 0.000 title abstract 3
- ANJQEDFWRSLVBR-VHUDCFPWSA-N methenolone Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C ANJQEDFWRSLVBR-VHUDCFPWSA-N 0.000 title abstract 3
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 title abstract 3
- 229960004719 nandrolone Drugs 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title 1
- 102000003752 Lipocalin 1 Human genes 0.000 abstract 2
- 108010057281 Lipocalin 1 Proteins 0.000 abstract 2
- 230000000857 drug effect Effects 0.000 abstract 2
- 210000004561 lacrimal apparatus Anatomy 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 210000000744 eyelid Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un objetivo de la presente invención es proporcionar un agente terapéutico para ojo seco novedoso que demuestre efectos terapéuticos para ojo seco superiores, y desde el punto de vista de la carga de administración de fármaco del paciente, sea capaz de demostrar un efecto medicinal durante un periodo largo de tiempo en tejido de glándula lacrimal después de la administración del mismo. Un agente terapéutico para ojo seco que comprende nandrolona o un éster del mismo o metenolona o un éster del mismo es terapéuticamente efectivo sobre el ojo seco ya que incrementa la cantidad de lágrima lipocalina (TL) en lágrimas, y los efectos medicinales se pueden demostrar durante un periodo largo de tiempo en tejido de glándula lacrimal al administrar un agente terapéutico para ojo seco que comprende nandrolona o un éster del mismo o metenolona o un éster del mismo a la piel del párpado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015076889 | 2015-04-03 | ||
| PCT/JP2016/060927 WO2016159350A1 (ja) | 2015-04-03 | 2016-04-01 | ナンドロロンまたはそのエステル、メテノロンまたはそのエステルを有効成分とするドライアイ治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017012708A true MX2017012708A (es) | 2018-01-09 |
Family
ID=57005003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012708A MX2017012708A (es) | 2015-04-03 | 2016-04-01 | Agente terapeutico para ojo seco que comprende nandrolona o ester del mismo o metenolona o ester del mismo como un ingrediente activo. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180071313A1 (es) |
| EP (1) | EP3278804A4 (es) |
| JP (1) | JP2016196453A (es) |
| KR (1) | KR20170132319A (es) |
| CN (1) | CN107427525A (es) |
| AU (1) | AU2016240948A1 (es) |
| BR (1) | BR112017021044A2 (es) |
| CA (1) | CA2981691A1 (es) |
| EA (1) | EA201792206A1 (es) |
| HK (2) | HK1243349A1 (es) |
| IL (1) | IL254828A0 (es) |
| MX (1) | MX2017012708A (es) |
| PH (1) | PH12017501796A1 (es) |
| SG (2) | SG11201707804YA (es) |
| TW (1) | TW201642868A (es) |
| WO (1) | WO2016159350A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0643581B1 (en) * | 1992-04-21 | 1999-10-20 | The Schepens Eye Research Institute, Inc. | Ocular androgen therapy in sjögren's syndrome |
| US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
| US6659985B2 (en) * | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| AU2003211877A1 (en) * | 2002-03-11 | 2003-09-22 | Takeda Chemical Industries, Ltd. | Remedies for sex hormone-dependent disease |
| WO2006094026A1 (en) * | 2005-03-02 | 2006-09-08 | Nascent Pharmaceuticals, Inc. | Pharmaceutically acceptable carrier for ophthalmic compositions |
| DE102006003512A1 (de) * | 2006-01-24 | 2007-08-02 | Bayer Schering Pharma Ag | Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| PT2285364E (pt) * | 2008-05-07 | 2015-02-24 | Univ California | Reposição e enriquecimento terapêutico de lubrificação da superficie ocular |
-
2016
- 2016-04-01 HK HK18102957.7A patent/HK1243349A1/en unknown
- 2016-04-01 TW TW105110451A patent/TW201642868A/zh unknown
- 2016-04-01 SG SG11201707804YA patent/SG11201707804YA/en unknown
- 2016-04-01 CN CN201680021224.8A patent/CN107427525A/zh active Pending
- 2016-04-01 CA CA2981691A patent/CA2981691A1/en not_active Abandoned
- 2016-04-01 US US15/563,108 patent/US20180071313A1/en not_active Abandoned
- 2016-04-01 EP EP16773230.4A patent/EP3278804A4/en not_active Withdrawn
- 2016-04-01 EA EA201792206A patent/EA201792206A1/ru unknown
- 2016-04-01 BR BR112017021044-4A patent/BR112017021044A2/pt not_active Application Discontinuation
- 2016-04-01 HK HK18106027.4A patent/HK1246644A1/zh unknown
- 2016-04-01 WO PCT/JP2016/060927 patent/WO2016159350A1/ja active Application Filing
- 2016-04-01 JP JP2016073886A patent/JP2016196453A/ja active Pending
- 2016-04-01 KR KR1020177031727A patent/KR20170132319A/ko not_active Withdrawn
- 2016-04-01 AU AU2016240948A patent/AU2016240948A1/en not_active Abandoned
- 2016-04-01 SG SG10201908566Y patent/SG10201908566YA/en unknown
- 2016-04-01 MX MX2017012708A patent/MX2017012708A/es unknown
-
2017
- 2017-09-29 PH PH12017501796A patent/PH12017501796A1/en unknown
- 2017-10-01 IL IL254828A patent/IL254828A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3278804A4 (en) | 2019-02-27 |
| IL254828A0 (en) | 2017-12-31 |
| BR112017021044A2 (pt) | 2018-07-24 |
| EP3278804A1 (en) | 2018-02-07 |
| AU2016240948A1 (en) | 2017-11-16 |
| US20180071313A1 (en) | 2018-03-15 |
| HK1246644A1 (zh) | 2018-09-14 |
| SG11201707804YA (en) | 2017-10-30 |
| HK1243349A1 (en) | 2018-07-13 |
| WO2016159350A1 (ja) | 2016-10-06 |
| CA2981691A1 (en) | 2016-10-06 |
| EA201792206A1 (ru) | 2018-02-28 |
| JP2016196453A (ja) | 2016-11-24 |
| PH12017501796A1 (en) | 2018-04-02 |
| KR20170132319A (ko) | 2017-12-01 |
| CN107427525A (zh) | 2017-12-01 |
| SG10201908566YA (en) | 2019-10-30 |
| TW201642868A (zh) | 2016-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
| WO2017158366A3 (en) | Ophthalmic delivery device and ophthalmic drug compositions | |
| PH12019500423A1 (en) | Pharmaceutical composition | |
| WO2015095772A3 (en) | Formulations and methods for targeted ocular delivery of therapeutic agents | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| MX368387B (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
| MX2017002374A (es) | Composiciones y metodos para tratar trastornos de la vision. | |
| BR112015021334A2 (pt) | formulações oculares para entrega de droga ao segmento posterior do olho | |
| CL2019001586A1 (es) | Insulina que contiene composiciones farmacéuticas. | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| EP3606570B8 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| EA202191683A1 (ru) | Средство, содержащее 4-фенилбутират, для профилактики или лечения пресбиопии | |
| MX379253B (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| CL2020001426A1 (es) | Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo. | |
| UA116499C2 (uk) | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| PH12017501796A1 (en) | Dry eye therapeutic agent comprising nandrolone or ester thereof or methenolone or ester thereof as an active ingredient |